Compare · ACET vs PALI
ACET vs PALI
Side-by-side comparison of Adicet Bio Inc. (ACET) and Palisade Bio Inc. (PALI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ACET focuses on Biotechnology: Pharmaceutical Preparations, while PALI focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- PALI is the larger of the two at $342.0M, about 4.5x ACET ($75.9M).
- Over the past year, ACET is down 34.9% and PALI is up 171.8% - PALI leads by 206.8 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- ACET has more recent analyst coverage (11 ratings vs 7 for PALI).
- Company
- Adicet Bio Inc.
- Palisade Bio Inc.
- Price
- $8.10-0.61%
- $1.96+4.81%
- Market cap
- $75.9M
- $342.0M
- 1M return
- +4.25%
- +9.50%
- 1Y return
- -34.94%
- +171.84%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 8
- Recent ratings
- 11
- 7
Adicet Bio Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
Palisade Bio Inc.
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
Latest ACET
- SEC Form 4 filed by President & CEO Schor Chen
- SEC Form 4 filed by Chief Scientific Officer Aftab Blake
- SEC Form 4 filed by Director Dubin Steve
- SEC Form 4 filed by Director Chodakewitz Jeffrey
- SEC Form 4 filed by Director Grissinger Michael
- SEC Form 4 filed by Director Sinclair Andrew
- SEC Form 4 filed by Director Peng Katie
- SEC Form 4 filed by Director Klickstein Lloyd
- Adicet Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: SEC Form 10-K/A filed by Adicet Bio Inc.
Latest PALI
- Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)
- Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
- Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)
- Chief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability
- CEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Palisade Bio Inc.
- Director Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
- Director Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)
- SEC Form 3 filed by new insider Baltera Robert Jr.